Brief: Medigene Discontinuation Of MDG1021 Development Program
Jan 28 (Reuters) - MEDIGENE AG MDG1k.DE :
* DISCONTINUATION OF MDG1021 DEVELOPMENT PROGRAM - FOCUS ON
SOLID
TUMORS
Source text for Eikon: ID:nPexXSwc1a
Further company coverage: MDG1k.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))
Recent news on Medigene AG
See all newsBrief: Medigene Files Application For The Opening Of Insolvency Proceedings
Brief: Medigene Files Patent For Unique Nk-Specific TCR Construct With European Patent Office
Brief: Medigene AG Says Co Amends Financial Guidance For 2024
Brief: Medigene AG Expands Protection Of KRAS Library With Filing Of New Patent Application
Brief: Medigene H1 Revenue EUR 4.5 Million